175 related articles for article (PubMed ID: 27749600)
1. TALEN-Mediated Knockout of CCR5 Confers Protection Against Infection of Human Immunodeficiency Virus.
Shi B; Li J; Shi X; Jia W; Wen Y; Hu X; Zhuang F; Xi J; Zhang L
J Acquir Immune Defic Syndr; 2017 Feb; 74(2):229-241. PubMed ID: 27749600
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV-1 Infection.
Romito M; Juillerat A; Kok YL; Hildenbeutel M; Rhiel M; Andrieux G; Geiger J; Rudolph C; Mussolino C; Duclert A; Metzner KJ; Duchateau P; Cathomen T; Cornu TI
Biotechnol J; 2021 Jan; 16(1):e2000023. PubMed ID: 33103367
[TBL] [Abstract][Full Text] [Related]
3. mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5.
Mock U; Machowicz R; Hauber I; Horn S; Abramowski P; Berdien B; Hauber J; Fehse B
Nucleic Acids Res; 2015 Jun; 43(11):5560-71. PubMed ID: 25964300
[TBL] [Abstract][Full Text] [Related]
4. Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1.
Badia R; Riveira-Muñoz E; Clotet B; Esté JA; Ballana E
J Antimicrob Chemother; 2014 Jul; 69(7):1755-9. PubMed ID: 24651827
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a chemokine receptor CCR5-negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype.
Binninger-Schinzel D; Müller D; Wolf T; Krause B; Meye B; Winskowsky G; Raupp S; Norley S; Brodt R; Werner A
J Med Virol; 2008 Feb; 80(2):192-200. PubMed ID: 18098144
[TBL] [Abstract][Full Text] [Related]
7. TALENs-mediated homozygous CCR5Δ32 mutations endow CD4+ U87 cells with resistance against HIV‑1 infection.
Yu AQ; Ding Y; Lu ZY; Hao YZ; Teng ZP; Yan SR; Li DS; Zeng Y
Mol Med Rep; 2018 Jan; 17(1):243-249. PubMed ID: 29115572
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice.
Hofer U; Henley JE; Exline CM; Mulhern O; Lopez E; Cannon PM
J Infect Dis; 2013 Nov; 208 Suppl 2(Suppl 2):S160-4. PubMed ID: 24151324
[TBL] [Abstract][Full Text] [Related]
9. mRNA Transfection of T-Lymphocytes by Electroporation.
Schwarze LI; Fehse B
Methods Mol Biol; 2021; 2285():217-226. PubMed ID: 33928556
[TBL] [Abstract][Full Text] [Related]
10. TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity.
Mussolino C; Alzubi J; Fine EJ; Morbitzer R; Cradick TJ; Lahaye T; Bao G; Cathomen T
Nucleic Acids Res; 2014 Jun; 42(10):6762-73. PubMed ID: 24792154
[TBL] [Abstract][Full Text] [Related]
11. CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection.
Wang W; Ye C; Liu J; Zhang D; Kimata JT; Zhou P
PLoS One; 2014; 9(12):e115987. PubMed ID: 25541967
[TBL] [Abstract][Full Text] [Related]
12. Targeted genome engineering in human induced pluripotent stem cells by penetrating TALENs.
Ru R; Yao Y; Yu S; Yin B; Xu W; Zhao S; Qin L; Chen X
Cell Regen; 2013; 2(1):5. PubMed ID: 25408877
[TBL] [Abstract][Full Text] [Related]
13. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4
Liu Z; Chen S; Jin X; Wang Q; Yang K; Li C; Xiao Q; Hou P; Liu S; Wu S; Hou W; Xiong Y; Kong C; Zhao X; Wu L; Li C; Sun G; Guo D
Cell Biosci; 2017; 7():47. PubMed ID: 28904745
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 4 (Tlr4) knockout rats produced by transcriptional activator-like effector nuclease (TALEN)-mediated gene inactivation.
Ferguson C; McKay M; Harris RA; Homanics GE
Alcohol; 2013 Dec; 47(8):595-9. PubMed ID: 24199847
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
[TBL] [Abstract][Full Text] [Related]
16. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage.
Xiao L; Owen SM; Goldman I; Lal AA; deJong JJ; Goudsmit J; Lal RB
Virology; 1998 Jan; 240(1):83-92. PubMed ID: 9448692
[TBL] [Abstract][Full Text] [Related]
17. Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application.
Schwarze LI; Głów D; Sonntag T; Uhde A; Fehse B
Gene Ther; 2021 Sep; 28(9):588-601. PubMed ID: 34112993
[TBL] [Abstract][Full Text] [Related]
18. Polyethylenimine-Mediated CCR5 Gene Knockout Using Transcription Activator-Like Effector Nucleases.
Jin L; Deng Y; He N; Wang L; Weng M
J Biomed Nanotechnol; 2018 Mar; 14(3):546-552. PubMed ID: 29663926
[TBL] [Abstract][Full Text] [Related]
19. Fully Automated One-Step Synthesis of Single-Transcript TALEN Pairs Using a Biological Foundry.
Chao R; Liang J; Tasan I; Si T; Ju L; Zhao H
ACS Synth Biol; 2017 Apr; 6(4):678-685. PubMed ID: 28103009
[TBL] [Abstract][Full Text] [Related]
20. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template.
Sather BD; Romano Ibarra GS; Sommer K; Curinga G; Hale M; Khan IF; Singh S; Song Y; Gwiazda K; Sahni J; Jarjour J; Astrakhan A; Wagner TA; Scharenberg AM; Rawlings DJ
Sci Transl Med; 2015 Sep; 7(307):307ra156. PubMed ID: 26424571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
